The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes

OBJECTIVE: In people with type 2 diabetes, sodium–glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular risk and progression of diabetic kidney disease. Our aim was to determine whether sotagliflozin (SOTA), a dual SGLT1i and SGLT2i, had favorable effects on clinical biomarkers suggestiv...

Descripción completa

Detalles Bibliográficos
Autores principales: van Raalte, Daniël H., Bjornstad, Petter, Persson, Frederik, Powell, David R., de Cassia Castro, Rita, Wang, Ping Stella, Liu, Minzhi, Heerspink, Hiddo J.L., Cherney, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2019
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905482/
https://www.ncbi.nlm.nih.gov/pubmed/31371432
http://dx.doi.org/10.2337/dc19-0937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905482/
https://www.ncbi.nlm.nih.gov/pubmed/31371432
http://dx.doi.org/10.2337/dc19-0937

Ejemplares similares